MATERIALS AND METHODS

Animals.
Healthy juvenile baboons (Papio cynocephalus or P anubis) were housed at the University of Washington Regional Primate Research Center, under American Association for Accreditation of Laboratory Animal Care approved conditions. Studies were conducted under Institutional Review Board and Animal Care and Use Committee approved protocols. All animals were provided with water, biscuits, and fruit ad libitum throughout the study. Baboons administered intravenous (IV) SCF had indwelling central venous catheters inserted via the femoral vein for use with a tether system previously described,I3 and were administered prophylactic antibiotics to prevent catheter-related infections. All study blood samples were drawn through the line. All procedures, including bone marrow biopsies, bone marrow aspirates, and blood draws for baboons administered subcutaneous injections (Sa) were performed after animals had been anesthetized with a combination of ketamine-HCl (Aveco, Fort Dodge, IA) and Xylazine (Haver, Shawnee, KS). Marrow samples were obtained from sites on the iliac crest, distal femur, proximal humerus, and proximal tibia. Biopsies were obtained using an 11-gauge Jamshidi biopsy needle and aspirates with a 13-gauge marrow aspiration needle. Marrow aspirates and peripheral blood samples for studies of CFC and expression of CD34 antigen were collected in 3-mL heparinized syringes. Marrow biopsies were fixed in B-5 fixative.
One to 2 mL blood samples were collected in EDTA twice weekly for complete blood counts (CBC) and reticulocyte counts. Differential cell counts ( 2 100 cells) on peripheral blood smears stained with Wright-Giemsa were determined for each CBC. Multiple sections from marrow core biopsies were stained with hematolyxin and eosin, and periodic acid Schiff. Slides were examined by the hematopathologist without prior knowledge of the treatment the animals had received. Sections from normal cellular baboon marrows had a cell to fat ratio of 1:l.
A total of 15 animals were studied before and during SCF treatment. Ten were administered SCF at 200 pg/kg/d, three by continuous IV infusion, four by twice daily, and three by single daily SQ injections. Two were administered SCF at 100 pglkgld, one by twice daily and the other by single daily SQ injection. Single animals were administered SCF at 50, 25, and 10 pg/kg/d as twice daily SQ injections. None of the animals had evidence for adverse reactions, skin rashes, or skin changes at the injection sites.
Recombinant human SCF as either the 164 (SCF'") or the 165 (SCF165) amino acid form was produced in Escherichia coli as preGrowth factors for in vivo administration. Purified material used for IV infusions was stored at -70°C and then thawed and diluted in 50 mL normal saline (Abbot Laboratories, Chicago, IL) containing 0.8% (vol/vol) sterile (0.2 km filtered) autologous baboon plasma immediately before starting the infusions.12 SCF used for SQ injection was stored at 4°C and the volumes per injection were I 1.0 mL at a single site. The doses of both unmodified SCF and PEG-SCF were based on the molecular weight of the unmodified protein, resulting in equal molar quantities per kilogram of body weight being administered to all animals.
Monoclonal antibodies (MoAbs) and immunofluorescent staining. MoAb 12-8 (CD34) and the isotype-matched control antibody H12C12 (antimouse Thy 1.2) were used to label peripheral blood and marrow cells, and were stained with phycoerythrin (PE)-conjugated goat antimouse IgM (p chain specific) antisera (Calbiochem, La Jolla, CA, or Biomeda, Foster City, CA), as previously de~cribed.'~ Baboon marrow and peripheral blood bu@ coat cells were isolated, residual red blood cells were lysed with ammonium chloride buffer, and the cells were cultured in 35-mm culture dishes (Nunc, Naperville, IL) at 5.0 X 104/mL for marrow cells and 1 x 1O5/mL for peripheral blood cells. All cells were cultured in two-layer agar cultures. The lower layer (1.0 mL) consisted of a-medium in 0.5% (wt/vol) agar (FMC, Rockland, ME, or Difco, Detroit, MI, for high proliferative potential-CFC [HPP-CFC] assays) supplemented with 25% fetal bovine serum (FBS; Hyclone, Logan, UT), 2% (wt/vol) bovine serum albumin (BSA; Fraction V; Sigma, St Louis, MO), gentamicin sulfate 100 bg/mL, and recombinant human growth factors IL-3 (100 ng/mL), granulocyte-macrophage-CSF (GM-CSF) (100 ng/mL), IL-6 (100 ng/mL), erythropoietin (Epo) (4 U/mL), and SCF (100 ng/mL) (purified material supplied by Amgen, Thousand Oaks, CA), or for HPP-CFC cultures, GM-CSF (30 ng/mL), IL-1 (20 ng/mL), IL-3 (20 ng/mL), and SCF (100 ng/mL). After the lower layer had gelled, cells in 0.5 mL a-medium, 25% FBS, 2% BSA, gentamicin, and 0.3% (wt/vol) agar were layered on top. Cultures were incubated at 37°C in a 5% 02, 5% COz, humidified incubator. At day 14 of culture, CFU-GM, BFU-E, and CFU-MIX were enumer-
CFC assays.
ated using an inverted microscope. Macroscopic BFU-E were defined as those greater than 0.5 mm in diameter. HPP-CFC, defined after the criteria of Bradley et al,15 and similar to those described by McNiece et all6 using human marrow, were enumerated after 21 days of culture and defined as unicentric colonies of 21.0 mm in diameter that had a dense center, while colonies lacking the dense center were defined as 2 1.0 Table 1) . Afterwards, there was a slight decrease in the number of WBC, but they remained elevated above pretreatment levels. After the SCF administration was discontinued, the WBC counts returned to pretreatment values within 7 to 10 days, as previously observed.12 Animals administered 100 and 50 pg/kg/d of SCF also had increased WBC counts, but to a lesser extent than animals administered 200 pg/kg/d (Table 1 ). The two animals administered 25 and 10 pg/kg/d of SCF showed no changes in peripheral blood WBC counts throughout or after the period of SCF administration. Reticulocyte counts increased within 3 to 7 days of starting SCF, as previously observed, but the magnitude of the increase was less in the animals administered 10 and 25 pglkg when compared with those administered 50,100, and 200 pg/kg.
Effect of SCF on CFC in peripheral blood. We next asked if SCF influenced the number of CFU-GM, BFU-E, CFUEffect of SCF on peripheral blood counts. (Table 2) , representing 10-fold to greater than 50-fold (mean k SEM = 27 f 9) increases in the relative numbers of circulating CFU-GM, and a 13-fold to greater than 120-fold (mean k SEM = 61 f 22) increase in the number of CFU-GM per milliliter of blood. The frequency of CFU-GM per 105 cells in circulation remained elevated (24-k 9-and 30-k 9-fold above pretreatment values on days 14 and 21, respectively) and then decreased during week 4 of SCF administration, but still remained significantly elevated. These changes were dose-dependent. Animals administered 100, 50, and 25 kg/kg/d had smaller increments in the relative numbers of circulating CFU-GM while receiving SCF, and again the numbers of detectable CFU-GM declined towards pretreatment values with the cessation of SCF treatment. The animal administered 10 p,g/kg had no significant increases in circulating CFU-GM during SCF treatment, which was not statistically different from results for untreated control animals. After SCF administration was stopped, the number of circulating CFU-GM, as well as other CFC, returned to pretreatment values.
BFU-E were detected in the blood of only 2 of 15 untreated animals studied at a single time point, and at only For
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onc timc point in onc of two untrcatcd animals studicd twicc wcckly for a pcriod of 3 wccks ( Table 2) . Nonc of thcsc BFU-E wcrc macroscopic ( 2 0 . 5 mm in diamctcr) in sizc (SCC Matcrials and Mcthods). All animals administcrcd 200 kg/kg/d of SCF had cvidcncc for significant incrcascs in BFU-E in thcir circulation. Significantly, 10% to 50% of thcsc circulating BFU-E, a s wcll a s a proportion of the CFU-GM, wcrc macroscopic (20.5 mm in diamctcr) in sizc, and thc frcqucncy of thcsc colonics was doscdcpcndcnt (Fig I) . Thcsc changcs in circulating BFU-E also wcrc dosc-rclatcd, although thcrc was ovcrlap in thc valucs for animals administcrcd 100 and 50 kg/kg. Thc animals administcrcd 25 and 10 pg/kg had valucs for circulating BFU-E that wcrc not statistically different from untrcatcd control animals.
Thc kinctics of thc incrcasc in numbcrs of CFC in blood was cxamincd in two animals (Fig 2) . Administration of 200 pg/kg/d of SCF induccd a significant changc in CFC of all typcs aftcr day 4. Thcsc changcs occurrcd bcforc thc significant incrcasc in thc total WRC counts was obscrvcd. Furthcrmorc, whcrcas mixcd lincagc colonics (CFU-MIX) wcrc not dctcctcd in culturcs o f blood samplcs from baboons bcforc trcatmcnt with SCF. they wcrc consistcntly dctcctcd in thc blood samplcs as early as day 5 and throughout thc pcriod of SCF administration.
Wc also assaycd a colony typc idcntificd as HPP-CFC in thc blood of six animals trcatcd with SCF (five wcrc administcrcd 200 pg/kg and onc was administcrcd 100 pg/kg of SCF). Thc HPP-CFC wcrc dcfincd as macroscopic colonics ( 2 1.0 mm in diamctcr) that wcrc prcscnt aftcr 3 wccks whcn cclls wcrc culturcd in thc prcscncc of SCF, IL-3. IL-I, and GM-CSF. Individual HPP-CFC contain up to 9 x IO5 cclls, consisting primarily of granulocytic, monocytic, and mast cell lincagcs, and a small portion of thcsc colonics also containcd cclls of thc crythrocytic lincagc if Epo also was prcscnt in thc culturcs (Bartclmcz SH, Andrcws RG, Bcrnstcin ID, unpublishcd obscrvations). HPP-CFC wcrc assaycd immcdiatcly bcforc starting SCF trcatmcnt in a11 six animals. For two animals, wc also assaycd thc blood twicc wcckly for a pcriod of 3 wccks bcforc starting SCF. In thcsc untrcatcd animals, bcforc SCF trcatmcnt, HPP-CFC wcrc rarcly dctcctcd in thc circulation (mcan ? SEM = 0.02 ? 0.02 HPP-CFC/IO' cclls). Aftcr starting trcatmcnt with SCF, thc numbcr of dctcctablc HPP-CFC in blood bcgan to incrcasc within 3 to 
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blood with light scatter properties of blast-like cells expressed high levels of CD34 antigen. After 7 days of SCF administered at 200 pg/kg/d, the frequency of CD34' cells in the blast-sized population had increased to 3.1% 2 0.7% (mean 2 SEM, N = 6 ) , whereas for animals administered 100 pg/kg, it was 1.4% f 0.2% (N = 2), and for the animals administcred 25 and 10 Fg/kg, it was 0.6% f 0.2% (N = 2). The frcqucncy of CD34+ cells in the blast-sized population was correlated with the frequency of CFC per 1B5 pcriphera1 blood bufy coat cells (Fig 3) .
Effects of SCF on bone marrow cellularily and motphologv.
Marrow biopsies on baboons administered 200 pg/kg/d of SCF showed that the marrow became markedly hypercellular (180% f 20% of normal) by day 7 (Fig 4) , and remained hypercellular throughout SCF treatment. Aftcr treatment was stopped, the ccllularity returned to prctreatmcnt values within 14 days. No discernible changes in marrow cellularity wcre observed in the animals administered 50, 25, and 10 Fg/kg of SCF, and intermediate levels of increased marrow cellularity were observed in animals administered 100 pg/kg of SCF.
The morphology of cells in marrow before and during SCF administration were determined by examination of Wright-Giemsa-stained cytospin preparations of marrow bufTy coat cells (Fig 5) . After Days of SCF Treatment For personal use only. on November 15, 2017 . by guest www.bloodjournal.org From 
DISCUSSION
In the present study, treatment with recombinant human SCF induced increased numbers of hematopoietic CFC of multiple types, including CFU-GM, BFU-E, CFU-MIX, and HPP-CFC, in blood and marrow. In blood, the increases in both the relative number (per 105) and absolute number (per milliliter) of CFC were dose-dependent. In some animals, the frequency of CFC in blood approached that of marrow. Even so, these changes occurred before there were significant increases in the peripheral blood WBC counts and were not associated with declining numbers of CFC in marrow, and as such these effects differ from those reported for G-CSF and GM-CSF.17-23 The fate of these numerous circulating CFC is not known, and large numbers of cells with intermediate levels of differentiation were not detected in the circulation.
In blood, where CD34+ cells normally are virtually undetectable, treatment with SCF induced increased numbers of CD34+ cells. Initial experiments to assess the function of these CD34+ cells have indicated that unfractionated mononuclear cells isolated from the blood after 10 to 11 days of SCF treatment can engraft lethally irradiated baboons, while the same number of cells isolated from the blood of untreated animals fail to rescue irradiated baboons (Andrews RG, Bensinger WI, Knitter GH, Appelbaum FR, Bernstein ID, and Zsebo KM, submitted for publication). Thus, precursors capable of at least short-term marrow repopulation are increased in the circulation with SCF treatment, but it remains to be determined if cells capable of long-term marrow repopulation have also been increased ia number.
A small proportion ( < 10%) of the circulating CD34+ cells had low or undetectable expression of HLA-DR p chain, while the majority of these cells expressed high levels of HLA-DR. A similarly small proportion of these circulating CD34+ cells also expressed T-and Bcell-associated differentiation antigens (Andrews RG, unpublished observations). With the exception of CD34+ HLA-DR' cells, it was not possible to identify cells with the phenotype of putative primitive precursor cells in human marrow because MoAbs that react with both human and baboon CD33, CD38, and 7B9 antigens were not a~ailable.2~-30
The results of the present study suggest that new CFC, of multiple types, are being generated in the hematopoietic tissues of SCF-treated animals, presumably from their precursors. This would be consistent with in vitro studies that showed that SCF can stimulate human marrow-derived precursors of CFC to generate CFC progeny.ll The effect of SCF on inducing increased numbers of CFC in bload also has been observed in mice administered recombinant rat SCF,31 and would be consistent with altered trafficking of CFC. Both G-CSF and GM-CSF have been reported to influence the circulation of not only CFC but also cells capable of at least short-term marrow repopulation in viv0,17,21-23 and it appears that SCF also may induce similar hematopoietic repopulating cells to circulate.
The ligand for c-kit is also a potent stimulator for mast cell proliferation in vitro.'" Mast cells were increased in number in the skin, marrow, and other tissues of these treated animals.32 However, we did not observe any adverse reactions to treatment suggesting mast cell activation.
The mechanisms by which SCF and other cytokines induce the circulation of hematopoietic progenitor cells and their precursors are presently unknown, nor is it known if the same or different classes of progenitor cells are induced to circulate by different cytokines. Understanding the basic biology of stem cell and progenitor cell trafficking may provide new approaches for clinical transplantation of both autologous and allogeneic hematopoietic stem cells. 
